HOME >> BIOLOGY >> NEWS
Clemson researcher receives Komen grant

rate.

Chen will use the Komen Foundation funding to further establish the molecular bases of the combination of PRL antagonist and Herceptin . "We hope that our research results will soon be translated into clinic and contribute to the battle against breast cancer," said Chen. More than 200,000 new U.S. breast cancer cases are diagnosed each year. Breast cancer is the most common form of cancer in women and can be diagnosed in men.

Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. If the spread is unabated, it can result in death. Cancer is caused by both external factors, such as radiation and chemicals, and internal factors, such as hormones, genetic mutations and immune conditions.


'"/>

Contact: Wen Y. Chen
wenc@clemson.edu
864-455-1457
Clemson University
28-May-2004


Page: 1 2

Related biology news :

1. Clemson University spin-off uses corn to make plastics, provide cleaner air
2. Clemson researcher places hope on pushy photons
3. Clemson University researcher reaches for the stars to prevent osteoporosis
4. Clemson launches S.C. DNA Learning Center
5. Clemson dedicates biotech research complex
6. Breakthrough Clemson research appears in Science
7. Clemson researcher takes part in breakthrough research on insects
8. Clemson researchers find bacteria fighter that does not promote bacterial resistance
9. Clemson researchers identify mental retardation gene
10. Clemson researchers create biosensors to protect nations food and water supplies
11. Clemson-led team makes breakthrough in controlling Bt resistance in pests

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... Summary This report provides all the information ... partnering interests and activities since 2010. Download the ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:3/2/2017)... MELBOURNE, Australia , March 2, 2017 ... Therapeutics Ltd (ASX: CYP), has signed an agreement ... researchers from the Monash Biomedicine Discovery Institute and Department ... , to conduct a further preclinical study to support ... the treatment of asthma.  Asthma is ...
(Date:2/28/2017)... 28, 2017   Acuant , a leading provider ... significant enhancements to new and core technologies building upon ... include mobile and desktop Acuant FRM TM facial ... a real time manual review of identity documents by ... the fastest and most accurate capture software to streamline ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... YORK , March 24, 2017 ... ended the trading session at 5,817.69, down 0.07%; the ... at 20,656.58; and the S&P 500 closed at 2,345.96, ... as 4 sectors closed in green, 4 sectors finished ... day. This Friday, Stock-Callers.com has initiated reports coverage on ...
(Date:3/23/2017)... Mar 23, 2017 Research and Markets ... Markets" report to their offering. ... The Global Market for ... in 2016 at a CAGR of 8.9%, ... non-energetic bioproducts into seven major product segments: bio-derived chemicals, biofuels, ...
(Date:3/23/2017)... Branford, CT (PRWEB) , ... March 23, 2017 ... ... Counsel, LLC, was recently selected by the Connecticut Technology Council (CTC) as a ... honored at CTC’s thirteenth annual Women of Innovation Awards Dinner. , The dinner ...
(Date:3/23/2017)... In today,s pre-market research, Stock-Callers.com ... Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals ... and Regulus Therapeutics Inc. (NASDAQ: RGLS ). ... its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn more ... ...
Breaking Biology Technology:
Cached News: